LEADER 01406nam  2200373Ia 450 
001 9910699395803321
005 20230902162117.0
035   $a(CKB)5470000002401954
035   $a(OCoLC)496297445
035   $a(EXLCZ)995470000002401954
100   $a20100108d2006      ua             0
101 0 $aeng
135   $auran|||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 00$aGuidance for industry$b[electronic resource] $eadverse reactions section of labeling for human prescription drug and biological products, content and format
210  1$aRockville, MD :$cU.S. Dept. of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research :$cCenter for Biologics Evaluation and Research,$d[2006]
215   $a1 online resource (13 pages)
300   $a"Labeling."
300   $a"January 2006."
517   $aGuidance for industry 
606   $aDrugs$xSide effects$zUnited States
606   $aDrugs$xLabeling$xGovernment policy$zUnited States
615  0$aDrugs$xSide effects
615  0$aDrugs$xLabeling$xGovernment policy
712 02$aCenter for Drug Evaluation and Research (U.S.)
712 02$aCenter for Biologics Evaluation and Research (U.S.)
801  0$bGPO
801  1$bGPO
906   $aBOOK
912   $a9910699395803321
996   $aGuidance for industry$93434577
997   $aUNINA